Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.

ABSTRACT: Breast cancer is one of the most common malignancies among women which is often treated with hormone therapy and chemotherapy. Despite the improvements in detection and treatment of breast cancer, the vast majority of breast cancer patients are diagnosed with metastatic disease either at the beginning of the disease or later during treatment. Still, the molecular mechanisms causing a therapy resistant metastatic breast cancer are still elusive. In the present study we addressed the function of the transcriptional activator ZRF1 during breast cancer progression. We provide evidence that ZRF1 plays an essential role for the early metastatic events in vitro and acts like a tumor suppressor protein during the progression of breast invasive ductal carcinoma into a more advanced stage. He

SUBMITTER: Kaymak A 

PROVIDER: S-EPMC6033359 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature